1
|
Qi T, Zhang J, Zhang K, Zhang W, Song Y, Lian K, Kan C, Han F, Hou N, Sun X. Unraveling the role of the FHL family in cardiac diseases: Mechanisms, implications, and future directions. Biochem Biophys Res Commun 2024; 694:149468. [PMID: 38183876 DOI: 10.1016/j.bbrc.2024.149468] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2023] [Revised: 12/23/2023] [Accepted: 01/02/2024] [Indexed: 01/08/2024]
Abstract
Heart diseases are a major cause of morbidity and mortality worldwide. Understanding the molecular mechanisms underlying these diseases is essential for the development of effective diagnostic and therapeutic strategies. The FHL family consists of five members: FHL1, FHL2, FHL3, FHL4, and FHL5/Act. These members exhibit different expression patterns in various tissues including the heart. FHL family proteins are implicated in cardiac remodeling, regulation of metabolic enzymes, and cardiac biomechanical stress perception. A large number of studies have explored the link between FHL family proteins and cardiac disease, skeletal muscle disease, and ovarian metabolism, but a comprehensive and in-depth understanding of the specific molecular mechanisms targeting FHL on cardiac disease is lacking. The aim of this review is to explore the structure and function of FHL family members, to comprehensively elucidate the mechanisms by which they regulate the heart, and to explore in depth the changes in FHL family members observed in different cardiac disorders, as well as the effects of mutations in FHL proteins on heart health.
Collapse
Affiliation(s)
- Tongbing Qi
- Department of Endocrinology and Metabolism, Affiliated Hospital of Weifang Medical University, Weifang, 261031, China; Clinical Research Center, Affiliated Hospital of Weifang Medical University, Weifang, 261031, China
| | - Jingwen Zhang
- Department of Endocrinology and Metabolism, Affiliated Hospital of Weifang Medical University, Weifang, 261031, China; Clinical Research Center, Affiliated Hospital of Weifang Medical University, Weifang, 261031, China
| | - Kexin Zhang
- Department of Endocrinology and Metabolism, Affiliated Hospital of Weifang Medical University, Weifang, 261031, China; Clinical Research Center, Affiliated Hospital of Weifang Medical University, Weifang, 261031, China
| | - Wenqiang Zhang
- Department of Endocrinology and Metabolism, Affiliated Hospital of Weifang Medical University, Weifang, 261031, China; Clinical Research Center, Affiliated Hospital of Weifang Medical University, Weifang, 261031, China; Department of Pathology, Affiliated Hospital of Weifang Medical University, Weifang, 261031, China
| | - Yixin Song
- Department of Endocrinology and Metabolism, Affiliated Hospital of Weifang Medical University, Weifang, 261031, China; Clinical Research Center, Affiliated Hospital of Weifang Medical University, Weifang, 261031, China
| | - Kexin Lian
- Department of Nephrology, Affiliated Hospital of Weifang Medical University, Weifang, 261031, China
| | - Chengxia Kan
- Department of Endocrinology and Metabolism, Affiliated Hospital of Weifang Medical University, Weifang, 261031, China; Clinical Research Center, Affiliated Hospital of Weifang Medical University, Weifang, 261031, China
| | - Fang Han
- Department of Endocrinology and Metabolism, Affiliated Hospital of Weifang Medical University, Weifang, 261031, China; Clinical Research Center, Affiliated Hospital of Weifang Medical University, Weifang, 261031, China; Department of Pathology, Affiliated Hospital of Weifang Medical University, Weifang, 261031, China
| | - Ningning Hou
- Department of Endocrinology and Metabolism, Affiliated Hospital of Weifang Medical University, Weifang, 261031, China.
| | - Xiaodong Sun
- Department of Endocrinology and Metabolism, Affiliated Hospital of Weifang Medical University, Weifang, 261031, China; Clinical Research Center, Affiliated Hospital of Weifang Medical University, Weifang, 261031, China.
| |
Collapse
|
2
|
Treat JA, Goodrow RJ, Bot CT, Haedo RJ, Cordeiro JM. Pharmacological enhancement of repolarization reserve in human induced pluripotent stem cells derived cardiomyocytes. Biochem Pharmacol 2019; 169:113608. [PMID: 31465775 DOI: 10.1016/j.bcp.2019.08.010] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2019] [Accepted: 08/14/2019] [Indexed: 12/24/2022]
Abstract
BACKGROUND Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) are used for many applications including safety pharmacology. However, a deficiency or complete absence of several K+ currents suggests repolarization reserve is low in hiPSC-CMs. We determined whether a dual Ito and IKr activator can improve repolarization reserve in hiPSC-CMs resulting in a more electrophysiologically mature phenotype. METHODS AND RESULTS Human iPSC were maintained on growth factor and differentiated into the cardiac phenotype by addition of selective Wnt molecules. Current and voltage clamp recordings in single cells were made using patch electrodes. Extracellular field potentials were made using a microelectrode array on hiPSC monolayers. Action potential recordings from hiPSC-CMs following application of an IKr inhibitor resulted in depolarization of the membrane potential and prolongation of the APD. A flattening of the T-wave was noted on the pseudo-ECG. In contrast, application of the IKr and Ito agonist, NS3623, resulted in hyperpolarization of the membrane, slowing of the spontaneous rate and shortening of the APD. Voltage clamp recording showed a significant increase in IKr; no enhancement of Ito in hiPSC-CMs was noted. AP clamp experiments revealed that IKr plays a role in both phase 3 repolarization and phase 4 depolarization. mRNA analysis revealed that KCNH2 is abundantly expressed in hiPSC-CM, consistent with electrophysiological recordings. CONCLUSIONS Although NS3623 is a dual Ito and IKr activator in ventricular myocytes, application of this compound to hiPSC-CMs enhanced only IKr and no effect on Ito was noted. Our results suggest IKr enhancement can improve repolarization reserve in this cell type. The disconnect between a dramatic increase in Ito in adult myocytes versus the lack of effect in hiPSC-CMs suggest that the translation of pharmacological effects in hiPSC-CM to adult myocytes should be viewed with caution.
Collapse
Affiliation(s)
- Jacqueline A Treat
- Department of Experimental Cardiology, Masonic Medical Research Institute, Utica, NY 13501 USA
| | - Robert J Goodrow
- Department of Experimental Cardiology, Masonic Medical Research Institute, Utica, NY 13501 USA
| | - Corina T Bot
- Nanion Technologies, 1 Naylon Ave. Suite C, Livingston, NJ 07039, USA
| | - Rodolfo J Haedo
- Nanion Technologies, 1 Naylon Ave. Suite C, Livingston, NJ 07039, USA
| | - Jonathan M Cordeiro
- Department of Experimental Cardiology, Masonic Medical Research Institute, Utica, NY 13501 USA.
| |
Collapse
|
3
|
Calloe K. Doctoral Dissertation: The transient outward potassium current in healthy and diseased hearts. Acta Physiol (Oxf) 2019; 225 Suppl 717:e13225. [PMID: 30628199 DOI: 10.1111/apha.13225] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2018] [Revised: 11/20/2018] [Accepted: 11/21/2018] [Indexed: 12/13/2022]
Affiliation(s)
- Kirstine Calloe
- Section for Anatomy; Biochemistry and Physiology; Department for Veterinary and Animal Sciences; Faculty of Health and Medical Sciences; University of Copenhagen; Frederiksberg C Denmark
| |
Collapse
|
4
|
Application of optical action potentials in human induced pluripotent stem cells-derived cardiomyocytes to predict drug-induced cardiac arrhythmias. J Pharmacol Toxicol Methods 2017; 87:53-67. [PMID: 28501647 DOI: 10.1016/j.vascn.2017.05.001] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2016] [Revised: 04/25/2017] [Accepted: 05/08/2017] [Indexed: 12/31/2022]
Abstract
INTRODUCTION Human induced pluripotent stem cell-derived cardiomyocytes (hiPS-CMs) are emerging as new and human-relevant source in vitro model for cardiac safety assessment that allow us to investigate a set of 20 reference drugs for predicting cardiac arrhythmogenic liability using optical action potential (oAP) assay. METHODS Here, we describe our examination of the oAP measurement using a voltage sensitive dye (Di-4-ANEPPS) to predict adverse compound effects using hiPS-CMs and 20 cardioactive reference compounds. Fluorescence signals were digitized at 10kHz and the records subsequently analyzed off-line. Cells were exposed to 30min incubation to vehicle or compound (n=5/dose, 4 doses/compound) that were blinded to the investigating laboratory. Action potential parameters were measured, including rise time (Trise) of the optical action potential duration (oAPD). RESULTS Significant effects on oAPD were sensitively detected with 11 QT-prolonging drugs, while oAPD shortening was observed with ICa-antagonists, IKr-activator or ATP-sensitive K+ channel (KATP)-opener. Additionally, the assay detected varied effects induced by 6 different sodium channel blockers. The detection threshold for these drug effects was at or below the published values of free effective therapeutic plasma levels or effective concentrations by other studies. DISCUSSION The results of this blinded study indicate that OAP is a sensitive method to accurately detect drug-induced effects (i.e., duration/QT-prolongation, shortening, beat rate, and incidence of early after depolarizations) in hiPS-CMs; therefore, this technique will potentially be useful in predicting drug-induced arrhythmogenic liabilities in early de-risking within the drug discovery phase.
Collapse
|
5
|
Lu HR, Gallacher DJ, Yan GX. Assessment of drug-induced proarrhythmia: The importance of study design in the rabbit left ventricular wedge model. J Pharmacol Toxicol Methods 2016; 81:151-60. [PMID: 27374776 DOI: 10.1016/j.vascn.2016.06.006] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2016] [Revised: 06/22/2016] [Accepted: 06/26/2016] [Indexed: 01/09/2023]
Abstract
In the present study, we investigated an impact of the stimulation rate on the detection of the proarrhythmic potential of 10 reference compounds with effects on different cardiac ion channels in the isolated arterially-perfused rabbit left ventricular wedge preparation. The compounds were tested in the wedge model using two distinct protocols; including baseline stimulation at 1-Hz followed by a brief period at 0.5-Hz, either without an additional brief period of 2-Hz stimulation (i.e. Protocol 1) or with 2-Hz stimulation (i.e. Protocol 2). As expected, QT-prolonging drugs (ibutilide and quinidine) prolonged the QT interval, similarly increased the Torsades de Pointes (TdP) score, and elicited early afterdepolarizations (EADs) in both protocols. HMR1556 and JNJ-303 (IKs blockers) also prolonged the QT interval up to 1μM similarly in both protocols. Nifedipine (Ca(2+) antagonist) shortened the QT interval, and reduced force of contraction similarly in both protocols. However, Na(+) channel blockers (Ia, Ib, Ic) widened the QRS duration more in Protocol 2 than in Protocol 1. Furthermore, it was only possible to detect non-TdP-like ventricular tachycardia/fibrillation (VT/VF) induced by Na(+) blockers and by QT-shortening drugs (levcromakalim and mallotoxin) using the 2-Hz stimulation (Protocol 2). Our data suggest that the inclusion of a brief period of fast stimulation at 2Hz is critical for detecting drug-induced slowing of conduction (QRS widening), QT shortening and associated (non-TdP-like) VT/VF, which are distinct from the QT prolongation/TdP proarrhythmia in isolated, arterially-perfused rabbit left ventricular wedges.
Collapse
Affiliation(s)
- Hua Rong Lu
- Global Safety Pharmacology, Discovery Sciences, Janssen Research & Development, Janssen Pharmaceutica NV, Belgium.
| | - David J Gallacher
- Global Safety Pharmacology, Discovery Sciences, Janssen Research & Development, Janssen Pharmaceutica NV, Belgium
| | - Gan-Xin Yan
- Lankenau Institute for Medical Research, Wynnewood, PA, USA
| |
Collapse
|
6
|
Schmitt N, Grunnet M, Olesen SP. Cardiac potassium channel subtypes: new roles in repolarization and arrhythmia. Physiol Rev 2014; 94:609-53. [PMID: 24692356 DOI: 10.1152/physrev.00022.2013] [Citation(s) in RCA: 160] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
About 10 distinct potassium channels in the heart are involved in shaping the action potential. Some of the K+ channels are primarily responsible for early repolarization, whereas others drive late repolarization and still others are open throughout the cardiac cycle. Three main K+ channels drive the late repolarization of the ventricle with some redundancy, and in atria this repolarization reserve is supplemented by the fairly atrial-specific KV1.5, Kir3, KCa, and K2P channels. The role of the latter two subtypes in atria is currently being clarified, and several findings indicate that they could constitute targets for new pharmacological treatment of atrial fibrillation. The interplay between the different K+ channel subtypes in both atria and ventricle is dynamic, and a significant up- and downregulation occurs in disease states such as atrial fibrillation or heart failure. The underlying posttranscriptional and posttranslational remodeling of the individual K+ channels changes their activity and significance relative to each other, and they must be viewed together to understand their role in keeping a stable heart rhythm, also under menacing conditions like attacks of reentry arrhythmia.
Collapse
|
7
|
Meng J, Shi C, Li L, Du Y, Xu Y. Compound ICA-105574 prevents arrhythmias induced by cardiac delayed repolarization. Eur J Pharmacol 2013; 718:87-97. [PMID: 24041920 DOI: 10.1016/j.ejphar.2013.09.011] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2013] [Revised: 08/27/2013] [Accepted: 09/04/2013] [Indexed: 01/14/2023]
Abstract
Impaired ventricular repolarization can lead to long QT syndrome (LQT), a proarrhythmic disease with high risk of developing lethal ventricular tachyarrhythmias. The compound ICA-105574 is a recently developed hERG activator and it enhances IKr current with very high potency by removing the channel inactivation. The present study was designed to investigate antiarrhythmic properties of ICA-105574. For comparison, the effects of another compound NS1643 was in-parallel assessed, which also acts primarily to attenuate channel inactivation with moderate potency. We found that both ICA-105574 and NS1643 concentration-dependently shortened action potential duration (APD) in ventricular myocytes, and QT/QTc intervals in isolated guinea-pig hearts. ICA-105574, but not NS1643, completely prevented ventricular arrhythmias in intact guinea-pig hearts caused by IKr and IKs inhibitors, although both ICA-105574 and NS1643 could reverse the drug-induced prolongation of APD in ventricular myocytes. Reversing prolongation of QT/QTc intervals and antagonizing the increases in transmural dispersion of repolarization and instability of the QT interval induced by IKr and IKs inhibitors contributed to antiarrhythmic effect of ICA-105574. Meanwhile, ICA-105574 at higher concentrations showed a potential proarrhythmic risk in normal hearts. Our results suggest that ICA-105574 has more efficient antiarrhythmic activity than NS1643. However, its potential proarrhythmic risk implies that benefits and risks should be seriously taken into consideration for further developing this type of hERG activators.
Collapse
Affiliation(s)
- Jing Meng
- The Key Laboratory of Neural and Vascular Biology, Ministry of Education; The Key Laboratory of New Drug Pharmacology and Toxicology, Department of Pharmacology, Hebei Medical University, Hebei Province, Shijiazhuang 050017, China; Department of Pharmaceutical Chemistry, Hebei Medical University, Shijiazhuang, China
| | | | | | | | | |
Collapse
|
8
|
|
9
|
Vandenberg JI, Perry MD, Perrin MJ, Mann SA, Ke Y, Hill AP. hERG K+ Channels: Structure, Function, and Clinical Significance. Physiol Rev 2012; 92:1393-478. [DOI: 10.1152/physrev.00036.2011] [Citation(s) in RCA: 463] [Impact Index Per Article: 38.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
The human ether-a-go-go related gene (hERG) encodes the pore-forming subunit of the rapid component of the delayed rectifier K+ channel, Kv11.1, which are expressed in the heart, various brain regions, smooth muscle cells, endocrine cells, and a wide range of tumor cell lines. However, it is the role that Kv11.1 channels play in the heart that has been best characterized, for two main reasons. First, it is the gene product involved in chromosome 7-associated long QT syndrome (LQTS), an inherited disorder associated with a markedly increased risk of ventricular arrhythmias and sudden cardiac death. Second, blockade of Kv11.1, by a wide range of prescription medications, causes drug-induced QT prolongation with an increase in risk of sudden cardiac arrest. In the first part of this review, the properties of Kv11.1 channels, including biogenesis, trafficking, gating, and pharmacology are discussed, while the second part focuses on the pathophysiology of Kv11.1 channels.
Collapse
Affiliation(s)
- Jamie I. Vandenberg
- Mark Cowley Lidwill Research Programme in Cardiac Electrophysiology, Victor Chang Cardiac Research Institute, Sydney, New South Wales, Australia; St Vincent's Clinical School, University of New South Wales, New South Wales, Australia; and University of Ottawa Heart Institute, Ottawa, Canada
| | - Matthew D. Perry
- Mark Cowley Lidwill Research Programme in Cardiac Electrophysiology, Victor Chang Cardiac Research Institute, Sydney, New South Wales, Australia; St Vincent's Clinical School, University of New South Wales, New South Wales, Australia; and University of Ottawa Heart Institute, Ottawa, Canada
| | - Mark J. Perrin
- Mark Cowley Lidwill Research Programme in Cardiac Electrophysiology, Victor Chang Cardiac Research Institute, Sydney, New South Wales, Australia; St Vincent's Clinical School, University of New South Wales, New South Wales, Australia; and University of Ottawa Heart Institute, Ottawa, Canada
| | - Stefan A. Mann
- Mark Cowley Lidwill Research Programme in Cardiac Electrophysiology, Victor Chang Cardiac Research Institute, Sydney, New South Wales, Australia; St Vincent's Clinical School, University of New South Wales, New South Wales, Australia; and University of Ottawa Heart Institute, Ottawa, Canada
| | - Ying Ke
- Mark Cowley Lidwill Research Programme in Cardiac Electrophysiology, Victor Chang Cardiac Research Institute, Sydney, New South Wales, Australia; St Vincent's Clinical School, University of New South Wales, New South Wales, Australia; and University of Ottawa Heart Institute, Ottawa, Canada
| | - Adam P. Hill
- Mark Cowley Lidwill Research Programme in Cardiac Electrophysiology, Victor Chang Cardiac Research Institute, Sydney, New South Wales, Australia; St Vincent's Clinical School, University of New South Wales, New South Wales, Australia; and University of Ottawa Heart Institute, Ottawa, Canada
| |
Collapse
|
10
|
Attenuated ventricular β-adrenergic response and reduced repolarization reserve in a rabbit model of chronic heart failure. J Cardiovasc Pharmacol 2012; 59:142-50. [PMID: 21992969 DOI: 10.1097/fjc.0b013e318238727a] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Animal models of pacing-induced heart failure (HF) are often associated with high acute mortality secondary to high pacing frequencies. The present study therefore exploits lower-frequency left ventricular pacing (300 beats per minute) in rabbits for 11 weeks to produce chronic HF with low acute mortality but profound structural, functional, and electrical remodeling and compare with nonpaced controls. Pacing increased heart weight/body weight ratio and decreased left ventricular fractional shortening in tachypaced only. Electrocardiogram recordings during sinus rhythm revealed QTc prolongation in paced animals. Ventricular arrhythmias or sudden death was not observed. Isoproterenol increased heart rate similarly in both groups but showed a blunted QT-shortening effect in tachypaced rabbits compared with controls. Langendorff experiments revealed significant monophasic action potential duration prolongation in tachypaced hearts and reduced contractility at cycle lengths from 400 to 250 ms. Hyperkalemia caused monophasic action potential duration shortening in controls, whereas crossover was seen in tachypaced with monophasic action potential duration prolongation at short cycle length. Hypokalemia prolonged monophasic action potential duration and increased short-term variability of repolarization in tachypaced hearts. A blunted monophasic action potential duration response was observed ex vivo in tachypaced hearts after isoproterenol. The HF rabbits showed structural, functional, and electrical remodeling but very low mortality. Isokalemic and hyperkalemic responses indicate downregulation of functional IKs. Increased short-term variability during hypokalemia unmasks a reduced repolarization reserve.
Collapse
|
11
|
Liu X, Limberis JT, Su Z, Houseman K, Diaz GJ, Gintant GA, Cox BF, Martin RL. Characterization of A-935142, a hERG enhancer, in the presence and absence of standard hERG blockers. Life Sci 2012; 90:607-11. [PMID: 22406079 DOI: 10.1016/j.lfs.2012.02.017] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2011] [Revised: 02/13/2012] [Accepted: 02/17/2012] [Indexed: 10/28/2022]
Abstract
AIMS In a previous study we found that A-935142 enhanced hERG current in a concentration-dependent manner by facilitating activation, reducing inactivation, and slowing deactivation (Su et al., 2009). A-935142 also shortened action potential duration (APD90) in canine Purkinje fibers and guinea pig atrial tissue. This study focused on the combined effects of the prototypical hERG enhancer, A-935142 and two hERG current blockers (sotalol and terfenadine). MAIN METHODS The whole-cell voltage clamp method with HEK 293 cells heterologously expressing the hERG channel (Kv 11.1) was used. KEY FINDINGS A-935142 did not compete with 3H-dofetilide binding, suggesting that A-935142 does not overlap the binding site of typical hERG blockers. In whole-cell voltage clamp studies we found: 1) 60 μM A-935142 enhanced hERG current in the presence of 150 μM sotalol (57.5±5.8%) to a similar extent as seen with A-935142 alone (55.6±5.1%); 2) 150 μM sotalol blocked hERG current in the presence of 60 μM A-935142 (43.5±1.5%) to a similar extent as that seen with sotalol alone (42.0±3.2%) and 3) during co-application, hERG current enhancement was followed by current blockade. Similar results were obtained with 60 nM terfenadine combined with A-935142. SIGNIFICANCE These results suggest that the hERG enhancer, A-935142 does not compete with these two known hERG blockers at their binding site within the hERG channel. This selective hERG current enhancement may be useful as a treatment for inherited or acquired LQTS (Casis et al., 2006).
Collapse
Affiliation(s)
- Xiaoqin Liu
- Department of Integrative Pharmacology, Abbott, 100 Abbott Park Road, Abbott Park, IL 60064-6119, USA.
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Möller C, Witchel H. Automated electrophysiology makes the pace for cardiac ion channel safety screening. Front Pharmacol 2011; 2:73. [PMID: 22131974 PMCID: PMC3222877 DOI: 10.3389/fphar.2011.00073] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2011] [Accepted: 11/06/2011] [Indexed: 01/14/2023] Open
Abstract
The field of automated patch-clamp electrophysiology has emerged from the tension between the pharmaceutical industry’s need for high-throughput compound screening versus its need to be conservative due to regulatory requirements. On the one hand, hERG channel screening was increasingly requested for new chemical entities, as the correlation between blockade of the ion channel coded by hERG and torsades de pointes cardiac arrhythmia gained increasing attention. On the other hand, manual patch-clamping, typically quoted as the “gold-standard” for understanding ion channel function and modulation, was far too slow (and, consequently, too expensive) for keeping pace with the numbers of compounds submitted for hERG channel investigations from pharmaceutical R&D departments. In consequence it became more common for some pharmaceutical companies to outsource safety pharmacological investigations, with a focus on hERG channel interactions. This outsourcing has allowed those pharmaceutical companies to build up operational flexibility and greater independence from internal resources, and allowed them to obtain access to the latest technological developments that emerged in automated patch-clamp electrophysiology – much of which arose in specialized biotech companies. Assays for nearly all major cardiac ion channels are now available by automated patch-clamping using heterologous expression systems, and recently, automated action potential recordings from stem-cell derived cardiomyocytes have been demonstrated. Today, most of the large pharmaceutical companies have acquired automated electrophysiology robots and have established various automated cardiac ion channel safety screening assays on these, in addition to outsourcing parts of their needs for safety screening.
Collapse
Affiliation(s)
- Clemens Möller
- InViTe Research Institute, Albstadt-Sigmaringen University Sigmaringen, Germany
| | | |
Collapse
|
13
|
Central and Peripheral GABA(A) Receptor Regulation of the Heart Rate Depends on the Conscious State of the Animal. Adv Pharmacol Sci 2011; 2011:578273. [PMID: 22162673 PMCID: PMC3226329 DOI: 10.1155/2011/578273] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2011] [Accepted: 09/05/2011] [Indexed: 12/29/2022] Open
Abstract
Intuitively one might expect that activation of GABAergic inhibitory neurons results in bradycardia. In conscious animals the opposite effect is however observed. GABAergic neurons in nucleus ambiguus hold the ability to control the activity of the parasympathetic vagus nerve that innervates the heart. Upon GABA activation the vagus nerve will be inhibited leaving less parasympathetic impact on the heart. The picture is however blurred in the presence of anaesthesia where both the concentration and type of anaesthetics can result in different effects on the cardiovascular system. This paper reviews cardiovascular outcomes of GABA activation and includes own experiments on anaesthetized animals and isolated hearts. In conclusion, the impact of changes in GABAergic input is very difficult to predict in these settings, emphasizing the need for experiments performed in conscious animals when aiming at determining the cardiovascular effects of compounds acting on GABAergic neurons.
Collapse
|
14
|
Varró A, Baczkó I. Cardiac ventricular repolarization reserve: a principle for understanding drug-related proarrhythmic risk. Br J Pharmacol 2011; 164:14-36. [PMID: 21545574 PMCID: PMC3171857 DOI: 10.1111/j.1476-5381.2011.01367.x] [Citation(s) in RCA: 139] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2010] [Revised: 02/22/2011] [Accepted: 03/02/2011] [Indexed: 12/11/2022] Open
Abstract
Cardiac repolarization abnormalities can be caused by a wide range of cardiac and non-cardiac compounds and may lead to the development of life-threatening Torsades de Pointes (TdP) ventricular arrhythmias. Drug-induced torsades de pointes is associated with unexpected and unexplained sudden cardiac deaths resulting in the withdrawal of several compounds in the past. To better understand the mechanism of such unexpected sudden cardiac deaths, the concept of repolarization reserve has recently emerged. According to this concept, pharmacological, congenital or acquired impairment of one type of transmembrane ion channel does not necessarily result in excessive repolarization changes because other repolarizing currents can take over and compensate. In this review, the major factors contributing to repolarization reserve are discussed in the context of their clinical significance in physiological and pathophysiological conditions including drug administration, genetic defects, heart failure, diabetes mellitus, gender, renal failure, hypokalaemia, hypothyroidism and athletes' sudden deaths. In addition, pharmacological support of repolarization reserve as a possible therapeutic option is discussed. Some methods for the quantitative estimation of repolarization reserve are also recommended. It is concluded that repolarization reserve should be considered by safety pharmacologists to better understand, predict and prevent previously unexplained drug-induced sudden cardiac deaths.
Collapse
Affiliation(s)
- András Varró
- Department of Pharmacology and Pharmacotherapy, University of Szeged, Szeged, Hungary.
| | | |
Collapse
|
15
|
Circulating KCNH2 current-activating factor in patients with heart failure and ventricular tachyarrhythmia. PLoS One 2011; 6:e19897. [PMID: 21625547 PMCID: PMC3098251 DOI: 10.1371/journal.pone.0019897] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2010] [Accepted: 04/19/2011] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND It is estimated that approximately half of the deaths in patients with HF are sudden and that the most likely causes of sudden death are lethal ventricular tachyarrhythmias such as ventricular tachycardia (VT) or fibrillation (VF). However, the precise mechanism of ventricular tachyarrhythmias remains unknown. The KCNH2 channel conducting the delayed rectifier K(+) current (I(Kr)) is recognized as the most susceptible channel in acquired long QT syndrome. Recent findings have revealed that not only suppression but also enhancement of I(Kr) increase vulnerability to major arrhythmic events, as seen in short QT syndrome. Therefore, we investigated the existence of a circulating KCNH2 current-modifying factor in patients with HF. METHODOLOGY/PRINCIPAL FINDINGS We examined the effects of serum of HF patients on recombinant I(Kr) recorded from HEK 293 cells stably expressing KCNH2 by using the whole-cell patch-clamp technique. Study subjects were 14 patients with non-ischemic HF and 6 normal controls. Seven patients had a history of documented ventricular tachyarrhythmias (VT: 7 and VF: 1). Overnight treatment with 2% serum obtained from HF patients with ventricular arrhythmia resulted in a significant enhancement in the peaks of I(Kr) tail currents compared to the serum from normal controls and HF patients without ventricular arrhythmia. CONCLUSIONS/SIGNIFICANCE Here we provide the first evidence for the presence of a circulating KCNH2 channel activator in patients with HF and ventricular tachyarrhythmias. This factor may be responsible for arhythmogenesis in patients with HF.
Collapse
|
16
|
Affiliation(s)
- T Jespersen
- Department of Biomedical Sciences 16.5, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
| |
Collapse
|
17
|
Larsen AP, Bentzen BH, Grunnet M. Differential effects of Kv11.1 activators on Kv11.1a, Kv11.1b and Kv11.1a/Kv11.1b channels. Br J Pharmacol 2011; 161:614-28. [PMID: 20880400 DOI: 10.1111/j.1476-5381.2010.00897.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
BACKGROUND AND PURPOSE K(v)11.1 channels are involved in regulating cellular excitability in various tissues including brain, heart and smooth muscle. In these tissues, at least two isoforms, K(v)11.1a and K(v)11.1b, with different kinetics, are expressed. K(v)11.1 activators are potential therapeutic agents, but their effects have only been tested on the K(v)11.1a isoform. In this study, the effects of two different K(v)11.1 activators, NS1643 and RPR260243, were characterized on K(v)11.1a and K(v)11.1b channels. EXPERIMENTAL APPROACH K(v)11.1a and K(v)11.1b channels were expressed in Xenopus laevis oocytes, and currents were measured using two-electrode voltage clamp. I/V curves and channel kinetics were measured before and after application of 30 µM NS1643 or 10 µM RPR260243. KEY RESULTS NS1643 increased steady-state currents through Kv11.1b several fold more than through K(v)11.1a channels, without affecting EC(50) values. NS1643 increased activation rates and decreased rates of inactivation, recovery from inactivation and deactivation for both channels. Except for activation, where effect of NS1643 was comparable, relative changes were greater for Kv11.1b than for K(v)11.1a. RPR260243 increased steady-state currents only through Kv11.1a channels, but slowed the process of deactivation for both channels primarily by decreasing time constant of slow deactivation. This effect was greater on K(v)11.1b than on K(v)11.1a. Effects of both compounds on heteromeric K(v)11.1a/K(v)11.1b channels were similar to those on K(v)11.1a. CONCLUSIONS AND IMPLICATIONS Both NS1643 and RPR260243 displayed differential effects on K(v)11.1a and K(v)11.1b channels, the effects being relatively more pronounced on K(v)11.1b channels. This affirms the importance of testing the effect of K(v)11.1 activators on different channel isoforms.
Collapse
Affiliation(s)
- A P Larsen
- The Danish National Research Foundation Centre for Cardiac Arrhythmia, Department of Biomedical Sciences, University of Copenhagen, Blegdamsvej 3, Copenhagen N, Denmark
| | | | | |
Collapse
|
18
|
Shah RR, Bjerregaard P, Gussak I. Drug-induced QT interval shortening: an emerging component in integrated assessment of cardiac safety of drugs. J Electrocardiol 2011; 43:386-9. [PMID: 20728017 DOI: 10.1016/j.jelectrocard.2010.06.008] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2010] [Indexed: 11/16/2022]
|
19
|
Grunnet M, Abbruzzese J, Sachse FB, Sanguinetti MC. Molecular determinants of human ether-à-go-go-related gene 1 (hERG1) K+ channel activation by NS1643. Mol Pharmacol 2010; 79:1-9. [PMID: 20876384 DOI: 10.1124/mol.110.067728] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Human ether-à-go-go-related gene 1 (hERG1) channels conduct the rapid delayed rectifier K+ current, I(Kr), an important determinant of action potential repolarization in mammals, including humans. Reduced I(Kr) function caused by mutations in KCNH2 or drug block of hERG1 channels prolongs the QT interval of the electrocardiogram and increases the risk of ventricular fibrillation and sudden cardiac death. Several activators of hERG1 channels have been discovered in recent years. These compounds shorten the duration of cardiac action potentials and have been proposed as a new therapeutic approach for the treatment of acquired or congenital long QT syndrome. We defined previously the mechanism of action of 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643), a compound that increases hERG1 currents by shifting the voltage-dependence of inactivation to more positive potentials. Here, we use scanning mutagenesis of hERG1 and functional characterization of 56 mutant channels heterologously expressed in Xenopus laevis oocytes to define the molecular determinants of the binding site for NS1643. Most point mutations did not alter response to the drug; however, 10 mutant channels had reduced sensitivity, and F619A and I567A exhibited enhanced activation by the drug. Some of these residues form a cluster and, together with molecular modeling, suggest that NS1643 binds to a pocket near the extracellular ends of the S5/S6 segments of two adjacent hERG1 channel subunits. This putative binding site differs from the sites described previously for two other hERG1 activators, (3R,4R)-4-[3-(6-methoxy-quinolin-4-yl)-3-oxo-propyl]-1-[3-(2,3,5-trifluoro-phenyl)-prop-2-ynyl]-piperidine-3-carboxylic acid (RPR260243) and 2-(4-[2-(3,4-dichloro-phenyl)-ethyl]-phenylamino)-benzoic acid (PD-118057).
Collapse
Affiliation(s)
- Morten Grunnet
- Department of Drug Discovery Portfolio Management, NeuroSearch A/S, Pederstrupvej 93, 2750 Ballerup, Denmark.
| | | | | | | |
Collapse
|
20
|
Castle NA. Pharmacological modulation of voltage-gated potassium channels as a therapeutic strategy. Expert Opin Ther Pat 2010; 20:1471-503. [PMID: 20726689 DOI: 10.1517/13543776.2010.513384] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
IMPORTANCE OF THE FIELD The human genome encodes at least 40 distinct voltage-gated potassium channel subtypes, which vary in regional expression, pharmacological and biophysical properties. Voltage-dependent potassium (Kv) channels help orchestrate many of the physiological and pathophysiological processes that promote and sometimes hinder the healthy functioning of our bodies. AREAS COVERED IN THIS REVIEW This review summarizes patent and scientific literature reports from the past decade highlighting the opportunities that Kv channels offer for the development of new therapeutic interventions for a wide variety of disorders. WHAT THE READER WILL GAIN The reader will gain an insight from an analysis of the associations of different Kv family members with disease processes, summary and evaluation of the development of therapeutically relevant pharmacological modulators of these channels, particularly focusing on proprietary agents being developed. TAKE HOME MESSAGE Development of new drugs that target Kv channels continue to be of great interest but is proving to be challenging. Nevertheless, opportunities for Kv channel modulators to have an impact on a wide range of disorders in the future remain an exciting prospect.
Collapse
|
21
|
Diness JG, Sørensen US, Nissen JD, Al-Shahib B, Jespersen T, Grunnet M, Hansen RS. Inhibition of Small-Conductance Ca
2+
-Activated K
+
Channels Terminates and Protects Against Atrial Fibrillation. Circ Arrhythm Electrophysiol 2010; 3:380-90. [DOI: 10.1161/circep.110.957407] [Citation(s) in RCA: 144] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background—
Recently, evidence has emerged that small-conductance Ca
2+
-activated K
+
(SK) channels are predominantly expressed in the atria in a number of species including human. In rat, guinea pig, and rabbit ex vivo and in vivo models of atrial fibrillation (AF), we used 3 different SK channel inhibitors, UCL1684,
N
-(pyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine (ICA), and NS8593, to assess the hypothesis that pharmacological inhibition of SK channels is antiarrhythmic.
Methods and Results—
In isolated, perfused guinea pig hearts, AF could be induced in all control hearts (n=7) with a combination of 1 μmol/L acetylcholine combined with electric stimulation. Pretreatment with 3 μmol/L NS8593, which had no effect on QT interval, prolonged the atrial effective refractory period by 37.1±7.7% (
P
<0.001) and prevented acetylcholine-induced AF (
P
<0.001, n=7). After AF induction, perfusion with NS8593 (10 μmol/L), UCL1684 (1 μmol/L), or ICA (1 μmol/L) terminated AF in all hearts, comparable to 10 μmol/L amiodarone. In isolated, perfused rat hearts, AF was induced with electric stimulation; 10 μmol/L NS8593 terminated AF and prevented reinduction of AF in all hearts (n=6,
P
<0.001). In all hearts, AF could be reinduced after washing. In isolated, perfused rabbit hearts, AF was induced with 10 μmol/L acetylcholine and burst pacing; 10 μmol/L NS8593 terminated AF and prevented reinduction of AF in all hearts (n=6,
P
<0.001). After washing, AF could be reinduced in 75% of the hearts (n=4,
P
=0.06). In an in vivo rat model of acute AF induced by burst pacing, injection of 5 mg/kg of either NS8593 or amiodarone shortened AF duration significantly to (23.2±20.0%,
P
<0.001, n=5, and 26.2±17.9%,
P
<0.001, n=5, respectively) as compared with injection of vehicle (96.3±33.2%, n=5).
Conclusions—
Inhibition of SK channels prolongs atrial effective refractory period without affecting QT interval and prevents and terminates AF ex vivo and in vivo, thus offering a promising new therapeutic opportunity in the treatment of AF.
Collapse
Affiliation(s)
- Jonas Goldin Diness
- From NeuroSearch A/S (J.G.D., U.S.S., B.A.-S., M.G., R.S.H.), Ballerup, Denmark; and the Danish National Research Foundation Centre for Cardiac Arrhythmia (J.G.D., J.D.N., T.J., M.G.), Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Ulrik S. Sørensen
- From NeuroSearch A/S (J.G.D., U.S.S., B.A.-S., M.G., R.S.H.), Ballerup, Denmark; and the Danish National Research Foundation Centre for Cardiac Arrhythmia (J.G.D., J.D.N., T.J., M.G.), Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Jakob Dahl Nissen
- From NeuroSearch A/S (J.G.D., U.S.S., B.A.-S., M.G., R.S.H.), Ballerup, Denmark; and the Danish National Research Foundation Centre for Cardiac Arrhythmia (J.G.D., J.D.N., T.J., M.G.), Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Baha Al-Shahib
- From NeuroSearch A/S (J.G.D., U.S.S., B.A.-S., M.G., R.S.H.), Ballerup, Denmark; and the Danish National Research Foundation Centre for Cardiac Arrhythmia (J.G.D., J.D.N., T.J., M.G.), Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Thomas Jespersen
- From NeuroSearch A/S (J.G.D., U.S.S., B.A.-S., M.G., R.S.H.), Ballerup, Denmark; and the Danish National Research Foundation Centre for Cardiac Arrhythmia (J.G.D., J.D.N., T.J., M.G.), Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Morten Grunnet
- From NeuroSearch A/S (J.G.D., U.S.S., B.A.-S., M.G., R.S.H.), Ballerup, Denmark; and the Danish National Research Foundation Centre for Cardiac Arrhythmia (J.G.D., J.D.N., T.J., M.G.), Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Rie Schultz Hansen
- From NeuroSearch A/S (J.G.D., U.S.S., B.A.-S., M.G., R.S.H.), Ballerup, Denmark; and the Danish National Research Foundation Centre for Cardiac Arrhythmia (J.G.D., J.D.N., T.J., M.G.), Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark
| |
Collapse
|
22
|
Abstract
Drug-induced long QT syndrome is a cardiac safety issue that all drugs seeking approval must currently address, in part via in vitro electrophysiological testing of the drug's effects on the function of the human Ether-à-go-go Related Gene (hERG) potassium channel. This regulatory strategy has also been scientifically successful, in that these in vitro assays are cheaper and faster than are many other surrogates for arrhythmogenic risk, including QT prolongation in humans and action potential prolongation in cardiomyocytes. In some ways hERG assays are also more sensitive to the underlying repolarization anomalies that lead to the risk of the Torsades de pointes arrhythmia. In addition, the higher throughput of hERG assays combined with advances in our understanding of the molecular structures underlying this pathophysiology have led to new approaches in the medicinal chemistry of "designing out" hERG liability from lead compounds. While generally effectual, hERG screening produces some false positives: drugs with an apparent liability that are known not to be clinically arrhythmogenic. New technologies continue to be developed to improve hERG screening, while further insights into the molecular pharmacology of hERG and cardiac repolarization are providing avenues to mitigate and make sense of the lack of torsadogenic specificity in extant hERG assays.
Collapse
Affiliation(s)
- Harry J Witchel
- Medical Research Building, Brighton and Sussex Medical School, University of Sussex, Falmer, Brighton, UK.
| |
Collapse
|
23
|
AKAR FADIG. Use-Dependent Modulation of Myocardial Conduction by a New Class of HERG Agonists: Deal Breaker or Cherry on Top? J Cardiovasc Electrophysiol 2010; 21:930-2. [DOI: 10.1111/j.1540-8167.2010.01747.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
24
|
Larsen AP, Olesen SP, Grunnet M, Poelzing S. Pharmacological activation of IKr impairs conduction in guinea pig hearts. J Cardiovasc Electrophysiol 2010; 21:923-9. [PMID: 20163495 DOI: 10.1111/j.1540-8167.2010.01733.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
INTRODUCTION The hERG (Kv11.1) potassium channel underlies cardiac I(Kr) and is important for cardiac repolarization. Recently, hERG agonists have emerged as potential antiarrhythmic drugs. As modulation of outward potassium currents has been suggested to modulate cardiac conduction, we tested the hypothesis that pharmacological activation of I(Kr) results in impaired cardiac conduction. METHODS AND RESULTS Cardiac conduction was assessed in Langendorff-perfused guinea pig hearts. Application of the hERG agonist NS3623 (10 microM) prolonged the QRS rate dependently. A significant prolongation (16 +/- 6%) was observed at short basic cycle length (BCL 90 ms) but not at longer cycle lengths (BCL 250 ms). The effect could be reversed by the I(Kr) blocker E4031 (1 microM). While partial I(Na) inhibition with flecainide (1 microM) alone prolonged the QRS (34 +/- 3%, BCL 250 ms), the QRS was further prolonged by 19 +/- 2% when NS3623 was added in the presence of flecainide. These data suggest that the effect of NS3623 was dependent on sodium channel availability. Surprisingly, in the presence of the voltage sensitive dye di-4-ANEPPS a similar potentiation of the effect of NS3623 was observed. With di-4-ANEPPS, NS3623 prolonged the QRS significantly (26 +/- 4%, BCL 250 ms) compared to control with a corresponding decrease in conduction velocity. CONCLUSION Pharmacological activation of I(Kr) by the hERG agonist NS3623 impairs cardiac conduction. The effect is dependent on sodium channel availability. These findings suggest a role for I(Kr) in modulating cardiac conduction and may have implications for the use of hERG agonists as antiarrhythmic drugs.
Collapse
Affiliation(s)
- Anders Peter Larsen
- Danish National Research Foundation Centre for Cardiac Arrhythmia, Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark
| | | | | | | |
Collapse
|
25
|
Grunnet M. Repolarization of the cardiac action potential. Does an increase in repolarization capacity constitute a new anti-arrhythmic principle? Acta Physiol (Oxf) 2010; 198 Suppl 676:1-48. [PMID: 20132149 DOI: 10.1111/j.1748-1716.2009.02072.x] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
The cardiac action potential can be divided into five distinct phases designated phases 0-4. The exact shape of the action potential comes about primarily as an orchestrated function of ion channels. The present review will give an overview of ion channels involved in generating the cardiac action potential with special emphasis on potassium channels involved in phase 3 repolarization. In humans, these channels are primarily K(v)11.1 (hERG1), K(v)7.1 (KCNQ1) and K(ir)2.1 (KCNJ2) being the responsible alpha-subunits for conducting I(Kr), I(Ks) and I(K1). An account will be given about molecular components, biophysical properties, regulation, interaction with other proteins and involvement in diseases. Both loss and gain of function of these currents are associated with different arrhythmogenic diseases. The second part of this review will therefore elucidate arrhythmias and subsequently focus on newly developed chemical entities having the ability to increase the activity of I(Kr), I(Ks) and I(K1). An evaluation will be given addressing the possibility that this novel class of compounds have the ability to constitute a new anti-arrhythmic principle. Experimental evidence from in vitro, ex vivo and in vivo settings will be included. Furthermore, conceptual differences between the short QT syndrome and I(Kr) activation will be accounted for.
Collapse
Affiliation(s)
- M Grunnet
- NeuroSearch A/S, Ballerup, and Danish National Research Foundation Centre for Cardiac Arrhythmia, University of Copenhagen, Denmark.
| |
Collapse
|
26
|
Horigome H, Nagashima M, Sumitomo N, Yoshinaga M, Ushinohama H, Iwamoto M, Shiono J, Ichihashi K, Hasegawa S, Yoshikawa T, Matsunaga T, Goto H, Waki K, Arima M, Takasugi H, Tanaka Y, Tauchi N, Ikoma M, Inamura N, Takahashi H, Shimizu W, Horie M. Clinical Characteristics and Genetic Background of Congenital Long-QT Syndrome Diagnosed in Fetal, Neonatal, and Infantile Life. Circ Arrhythm Electrophysiol 2010; 3:10-7. [DOI: 10.1161/circep.109.882159] [Citation(s) in RCA: 90] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Hitoshi Horigome
- From the Department of Child Health (H.H.), Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan; the Department of Cardiology (M.N.), Aichi Children’s Health and Medical Center, Ohbu, Japan; the Department of Pediatrics and Child Health (N.S.), Nihon University School of Medicine, Tokyo, Japan; the Department of Pediatrics (M.Y.), National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan; the Department of Cardiology (H.U.), Fukuoka Children’s
| | - Masami Nagashima
- From the Department of Child Health (H.H.), Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan; the Department of Cardiology (M.N.), Aichi Children’s Health and Medical Center, Ohbu, Japan; the Department of Pediatrics and Child Health (N.S.), Nihon University School of Medicine, Tokyo, Japan; the Department of Pediatrics (M.Y.), National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan; the Department of Cardiology (H.U.), Fukuoka Children’s
| | - Naokata Sumitomo
- From the Department of Child Health (H.H.), Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan; the Department of Cardiology (M.N.), Aichi Children’s Health and Medical Center, Ohbu, Japan; the Department of Pediatrics and Child Health (N.S.), Nihon University School of Medicine, Tokyo, Japan; the Department of Pediatrics (M.Y.), National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan; the Department of Cardiology (H.U.), Fukuoka Children’s
| | - Masao Yoshinaga
- From the Department of Child Health (H.H.), Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan; the Department of Cardiology (M.N.), Aichi Children’s Health and Medical Center, Ohbu, Japan; the Department of Pediatrics and Child Health (N.S.), Nihon University School of Medicine, Tokyo, Japan; the Department of Pediatrics (M.Y.), National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan; the Department of Cardiology (H.U.), Fukuoka Children’s
| | - Hiroya Ushinohama
- From the Department of Child Health (H.H.), Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan; the Department of Cardiology (M.N.), Aichi Children’s Health and Medical Center, Ohbu, Japan; the Department of Pediatrics and Child Health (N.S.), Nihon University School of Medicine, Tokyo, Japan; the Department of Pediatrics (M.Y.), National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan; the Department of Cardiology (H.U.), Fukuoka Children’s
| | - Mari Iwamoto
- From the Department of Child Health (H.H.), Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan; the Department of Cardiology (M.N.), Aichi Children’s Health and Medical Center, Ohbu, Japan; the Department of Pediatrics and Child Health (N.S.), Nihon University School of Medicine, Tokyo, Japan; the Department of Pediatrics (M.Y.), National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan; the Department of Cardiology (H.U.), Fukuoka Children’s
| | - Junko Shiono
- From the Department of Child Health (H.H.), Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan; the Department of Cardiology (M.N.), Aichi Children’s Health and Medical Center, Ohbu, Japan; the Department of Pediatrics and Child Health (N.S.), Nihon University School of Medicine, Tokyo, Japan; the Department of Pediatrics (M.Y.), National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan; the Department of Cardiology (H.U.), Fukuoka Children’s
| | - Koh Ichihashi
- From the Department of Child Health (H.H.), Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan; the Department of Cardiology (M.N.), Aichi Children’s Health and Medical Center, Ohbu, Japan; the Department of Pediatrics and Child Health (N.S.), Nihon University School of Medicine, Tokyo, Japan; the Department of Pediatrics (M.Y.), National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan; the Department of Cardiology (H.U.), Fukuoka Children’s
| | - Satoshi Hasegawa
- From the Department of Child Health (H.H.), Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan; the Department of Cardiology (M.N.), Aichi Children’s Health and Medical Center, Ohbu, Japan; the Department of Pediatrics and Child Health (N.S.), Nihon University School of Medicine, Tokyo, Japan; the Department of Pediatrics (M.Y.), National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan; the Department of Cardiology (H.U.), Fukuoka Children’s
| | - Tadahiro Yoshikawa
- From the Department of Child Health (H.H.), Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan; the Department of Cardiology (M.N.), Aichi Children’s Health and Medical Center, Ohbu, Japan; the Department of Pediatrics and Child Health (N.S.), Nihon University School of Medicine, Tokyo, Japan; the Department of Pediatrics (M.Y.), National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan; the Department of Cardiology (H.U.), Fukuoka Children’s
| | - Tamotsu Matsunaga
- From the Department of Child Health (H.H.), Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan; the Department of Cardiology (M.N.), Aichi Children’s Health and Medical Center, Ohbu, Japan; the Department of Pediatrics and Child Health (N.S.), Nihon University School of Medicine, Tokyo, Japan; the Department of Pediatrics (M.Y.), National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan; the Department of Cardiology (H.U.), Fukuoka Children’s
| | - Hiroko Goto
- From the Department of Child Health (H.H.), Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan; the Department of Cardiology (M.N.), Aichi Children’s Health and Medical Center, Ohbu, Japan; the Department of Pediatrics and Child Health (N.S.), Nihon University School of Medicine, Tokyo, Japan; the Department of Pediatrics (M.Y.), National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan; the Department of Cardiology (H.U.), Fukuoka Children’s
| | - Kenji Waki
- From the Department of Child Health (H.H.), Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan; the Department of Cardiology (M.N.), Aichi Children’s Health and Medical Center, Ohbu, Japan; the Department of Pediatrics and Child Health (N.S.), Nihon University School of Medicine, Tokyo, Japan; the Department of Pediatrics (M.Y.), National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan; the Department of Cardiology (H.U.), Fukuoka Children’s
| | - Masaki Arima
- From the Department of Child Health (H.H.), Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan; the Department of Cardiology (M.N.), Aichi Children’s Health and Medical Center, Ohbu, Japan; the Department of Pediatrics and Child Health (N.S.), Nihon University School of Medicine, Tokyo, Japan; the Department of Pediatrics (M.Y.), National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan; the Department of Cardiology (H.U.), Fukuoka Children’s
| | - Hisashi Takasugi
- From the Department of Child Health (H.H.), Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan; the Department of Cardiology (M.N.), Aichi Children’s Health and Medical Center, Ohbu, Japan; the Department of Pediatrics and Child Health (N.S.), Nihon University School of Medicine, Tokyo, Japan; the Department of Pediatrics (M.Y.), National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan; the Department of Cardiology (H.U.), Fukuoka Children’s
| | - Yasuhiko Tanaka
- From the Department of Child Health (H.H.), Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan; the Department of Cardiology (M.N.), Aichi Children’s Health and Medical Center, Ohbu, Japan; the Department of Pediatrics and Child Health (N.S.), Nihon University School of Medicine, Tokyo, Japan; the Department of Pediatrics (M.Y.), National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan; the Department of Cardiology (H.U.), Fukuoka Children’s
| | - Nobuo Tauchi
- From the Department of Child Health (H.H.), Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan; the Department of Cardiology (M.N.), Aichi Children’s Health and Medical Center, Ohbu, Japan; the Department of Pediatrics and Child Health (N.S.), Nihon University School of Medicine, Tokyo, Japan; the Department of Pediatrics (M.Y.), National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan; the Department of Cardiology (H.U.), Fukuoka Children’s
| | - Masanobu Ikoma
- From the Department of Child Health (H.H.), Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan; the Department of Cardiology (M.N.), Aichi Children’s Health and Medical Center, Ohbu, Japan; the Department of Pediatrics and Child Health (N.S.), Nihon University School of Medicine, Tokyo, Japan; the Department of Pediatrics (M.Y.), National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan; the Department of Cardiology (H.U.), Fukuoka Children’s
| | - Noboru Inamura
- From the Department of Child Health (H.H.), Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan; the Department of Cardiology (M.N.), Aichi Children’s Health and Medical Center, Ohbu, Japan; the Department of Pediatrics and Child Health (N.S.), Nihon University School of Medicine, Tokyo, Japan; the Department of Pediatrics (M.Y.), National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan; the Department of Cardiology (H.U.), Fukuoka Children’s
| | - Hideto Takahashi
- From the Department of Child Health (H.H.), Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan; the Department of Cardiology (M.N.), Aichi Children’s Health and Medical Center, Ohbu, Japan; the Department of Pediatrics and Child Health (N.S.), Nihon University School of Medicine, Tokyo, Japan; the Department of Pediatrics (M.Y.), National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan; the Department of Cardiology (H.U.), Fukuoka Children’s
| | - Wataru Shimizu
- From the Department of Child Health (H.H.), Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan; the Department of Cardiology (M.N.), Aichi Children’s Health and Medical Center, Ohbu, Japan; the Department of Pediatrics and Child Health (N.S.), Nihon University School of Medicine, Tokyo, Japan; the Department of Pediatrics (M.Y.), National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan; the Department of Cardiology (H.U.), Fukuoka Children’s
| | - Minoru Horie
- From the Department of Child Health (H.H.), Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan; the Department of Cardiology (M.N.), Aichi Children’s Health and Medical Center, Ohbu, Japan; the Department of Pediatrics and Child Health (N.S.), Nihon University School of Medicine, Tokyo, Japan; the Department of Pediatrics (M.Y.), National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan; the Department of Cardiology (H.U.), Fukuoka Children’s
| |
Collapse
|
27
|
Shah RR. Drug-induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectives. Br J Pharmacol 2010; 159:58-69. [PMID: 19563537 PMCID: PMC2823352 DOI: 10.1111/j.1476-5381.2009.00191.x] [Citation(s) in RCA: 83] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2008] [Revised: 01/07/2009] [Accepted: 01/14/2009] [Indexed: 01/08/2023] Open
Abstract
ATP-dependent potassium channel openers such as pinacidil and levcromakalim have long been known to shorten action potential duration and to be profibrillatory in non-clinical models, raising concerns on the clinical safety of drugs that shorten QT interval. Routine non-clinical evaluation of new drugs for their potential to affect cardiac repolarization has revealed that drugs may also shorten QT interval. The description of congenital short QT syndrome in 2000, together with the associated arrhythmias, suggests that drug-induced short QT interval may be proarrhythmic, and an uncanny parallel is evolving between our appreciation of the short and the long QT intervals. Epidemiological studies report an over-representation of short QT interval values in patients with idiopathic ventricular fibrillation. Therefore, as new compounds that shorten QT interval are progressed further into clinical development, questions will inevitably arise on their safety. Arising from the current risk-averse clinical and regulatory environment and concerns on proarrhythmic safety of drugs, together with our lack of a better understanding of the clinical significance of short QT interval, new drugs that substantially shorten QT interval will likely receive an unfavourable regulatory review unless these drugs fulfil an unmet clinical need. This review provides estimates of parameters of QT shortening that may be of potential clinical significance. Rufinamide, a recently approved anticonvulsant, illustrates the current regulatory approach to drugs that shorten QT interval. However, to further substantiate or confirm the safety of these drugs, their approval may well be conditional upon large-scale post-marketing studies with a focus on cardiac safety.
Collapse
Affiliation(s)
- Rashmi R Shah
- Medicines and Healthcare products Regulatory Agency, London, UK.
| |
Collapse
|
28
|
Diness JG, Hansen RS, Nissen JD, Jespersen T, Grunnet M. Antiarrhythmic effect of IKr activation in a cellular model of LQT3. Heart Rhythm 2009; 6:100-6. [DOI: 10.1016/j.hrthm.2008.10.020] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/25/2008] [Accepted: 10/13/2008] [Indexed: 10/21/2022]
|
29
|
hERG1 channel activators: A new anti-arrhythmic principle. PROGRESS IN BIOPHYSICS AND MOLECULAR BIOLOGY 2008; 98:347-62. [DOI: 10.1016/j.pbiomolbio.2009.01.002] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
30
|
Hansen RS, Olesen SP, Rønn LCB, Grunnet M. In Vivo Effects of the IKr Agonist NS3623 on Cardiac Electrophysiology of the Guinea Pig. J Cardiovasc Pharmacol 2008; 52:35-41. [DOI: 10.1097/fjc.0b013e31817dd013] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|
31
|
Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines. Br J Pharmacol 2008; 154:1427-38. [PMID: 18493243 PMCID: PMC2440085 DOI: 10.1038/bjp.2008.191] [Citation(s) in RCA: 106] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Background and purpose: The regulatory guidelines (ICHS7B) recommending inhibition of the delayed rectifier K+ current (IKr), carried by human ether-a-go-go-related gene (hERG) channels in cardiac cells (the hERG test), as a ‘first line' test for identifying compounds inducing QT prolongation, have limitations, some of which are outlined here. Experimental approach: hERG current was measured in HEK293 cells, stably transfected with hERG channels; action potential duration (APD) and arrhythmogenic effects were measured in isolated Purkinje fibres and perfused hearts from rabbits. Key results: 576 compounds were screened in the hERG test: 58% were identified as hERG inhibitors, 39% had no effect and 3% were classified as stimulators. Of the hERG inhibitors, 92 were tested in the APD assay: 55.4% of these prolonged APD, 28.3% had no effect and 16.3% shortened APD. Of the 70 compounds without effect on hERG channels, 54.3% did not affect APD, 25.7% prolonged, while 20% significantly shortened APD. Dofetilide (hERG inhibitor; IC50, 29 nM) prolonged QT and elicited early after-depolarizations and/or torsade de pointes (TdP) in isolated hearts. Mallotoxin and NS1643 (hERG current stimulators at 3 μM), levcromakalim and nicorandil (no effect on hERG current), all significantly shortened APD and QT, and elicited ventricular fibrillation (VF) in isolated hearts. Conclusion and implications: The hERG assay alone did not adequately identify drugs inducing QT prolongation. It is also important to detect drug-induced QT shortening, as this effect is associated with a potential risk for ventricular tachycardia and VF, the latter being invariably fatal, whereas TdP has an ∼15–25% incidence of death.
Collapse
|